Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efbemalenograstim alfa primary prophylaxis for chemotherapy-induced neutropenia in breast cancer during EC chemotherapy
ChiCTR2300078792Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efbemalenograstim alfa in neutropenia, sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Incidence of grade 3 or higher neutropenia during the entire EC chemotherapy period. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on ChiCTR2300078792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078792.